94 T1-T2 patients, with a baseline PSA lower or equal to 10ng/ml, treated with Ablatherm-HIFU as first choice therapy were included in a study conducted in Lyon (1). A very strict evaluation criterion, combining both the biopsy and the PSA stability was defined. Even with this strict criterion, a 77.5% Disease Free Rate (DFR) was obtained, with a follow-up up to 80 months.

When results were stratified according to the cancer aggressiveness (given by the Gleason score), better results (85% Disease Free) were observed with the less aggressive cancers. It is also interesting to note that all the failures after Ablatherm-HIFU treatment occurred early during the patient follow-up: within 20 months.